amiloride has been researched along with sorafenib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Mihaila, RG | 1 |
| Chang, CS; Chang, JG; Chang, WH; Chang, YS; Chen, YC; Chen, YT; Hsu, KC; Lee, CC; Lin, SY; Liu, TY; Wu, YC; Yang, JM | 1 |
| Kinoshita, Y; Matsuda, Y; Osawa, M; Wakai, T | 1 |
2 review(s) available for amiloride and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
A minireview on NHE1 inhibitors. A rediscovered hope in oncohematology.
Topics: Amiloride; Antineoplastic Agents; Apoptosis; Cation Transport Proteins; Cell Line, Tumor; DNA Damage; Drug Interactions; fms-Like Tyrosine Kinase 3; Genes, abl; Guanidines; Heme Oxygenase-1; Humans; Hydrogen-Ion Concentration; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mutation; Niacinamide; Osmolar Concentration; Patents as Topic; Phenylurea Compounds; Protein Kinase Inhibitors; Signal Transduction; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Sorafenib; Sulfones; Tumor Hypoxia; Up-Regulation | 2015 |
3 other study(ies) available for amiloride and sorafenib
| Article | Year |
|---|---|
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Alternative splicing in human cancer cells is modulated by the amiloride derivative 3,5-diamino-6-chloro-N-(N-(2,6-dichlorobenzoyl)carbamimidoyl)pyrazine-2-carboxide.
Topics: Alternative Splicing; Amiloride; Animals; Apoptosis; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; G2 Phase; Gene Expression Regulation, Neoplastic; Genome, Human; Heterogeneous-Nuclear Ribonucleoproteins; Histones; Humans; Mice, Inbred BALB C; Mitosis; Models, Molecular; Molecular Targeted Therapy; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Pyrimidines; RNA, Messenger; Serine-Arginine Splicing Factors; Sorafenib; Xenograft Model Antitumor Assays | 2019 |
Urokinase-type Plasminogen Activator Is a Therapeutic Target for Overcoming Sorafenib Resistance in Hepatoma Cells.
Topics: Amiloride; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Hepatocellular; Cell Proliferation; Drug Resistance, Neoplasm; Hep G2 Cells; Humans; Liver Neoplasms; Male; Membrane Proteins; Mice, Inbred BALB C; Mice, Nude; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; RNA Interference; RNA, Small Interfering; Sorafenib; Xenograft Model Antitumor Assays | 2021 |